Shenzhen NewDEL Biotech Co., Ltd. ("NewDEL Biotech"）and Nanjing Jingzhun Biotechnology Co., Ltd. ( "Jingzhun Biotech") recently announced the signing of a new drug development cooperation agreement to jointly develop immunotherapies targeting complement targets. This collaboration combines NewDEL Biotech's DNA-encoded compound library and its unique technology for live cell screening with Jingzhun Biotech's expertise in antigen preparation, stable cell line construction, cell activity validation systems, and GPCR structure analysis, particularly focusing on multi-transmembrane proteins (especially the GPCR family). The complementary strengths of both parties signify a significant step forward in NewDEL Biotech's commercial model for new drug development based on the DEL3.0 technology platform.

"We are honored to collaborate with Jingzhun Biotech to develop anti-tumor drugs with significant features and clinical value through complementary resource advantages. NewDEL Biotech continues to focus on and develop landing points for the advantages of DEL3.0, maintaining interest in resources that can be well combined with DEL3.0 technology. This collaboration is an opportunity for both companies to share resources and complement each other's expertise, and it is also a milestone achievement in the steady advancement of NewDEL Biotech's new drug joint development commercial model.

Dr. Tan Jingquan, founder of Jingzhun Biotech, stated, "The collaboration between Jingzhun Biotech and NewDEL Biotech in new drug development combines the research and development characteristics and advantages of both parties, jointly investing in the development of distinctively featured new drugs. We believe this collaboration can create a win-win situation for both parties and develop a more competitive new drug development cooperation model."